The saxenda market research report is one of a series of new reports that provides saxenda market statistics, including saxenda industry global market size, regional shares, competitors with saxenda market share, detailed saxenda market segments, market trends and opportunities, and any further data you may need to thrive in the saxenda industry. This saxenda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to growing personalized medicine, expanding healthcare infrastructure, rising demand for non-surgical weight loss solutions, and increasing use of digital health tools. Major trends in the forecast period include the emergence of combination therapies for weight loss, increasing availability of prescription weight loss medications, rising adoption of digital health and fitness apps, integration of weight management solutions into primary care, and greater focus on sustainable lifestyle changes.
The increasing prevalence of obesity is expected to drive the growth of the Saxenda market in the coming years. Obesity, which is characterized by excessive body fat, increases the risk of various health conditions such as diabetes, heart disease, and certain cancers. Factors contributing to the rising prevalence of obesity include poor diets, sedentary lifestyles, urbanization, genetic predispositions, and hormonal imbalances. Saxenda aids in combating obesity by regulating appetite through liraglutide, an active ingredient that mimics the natural hormone GLP-1, promoting feelings of fullness, reducing caloric intake, and supporting sustainable weight loss when combined with a healthy diet and regular exercise. For example, according to a May 2024 report by the Office for Health Improvement and Disparities (OHID), around 64% of adults in England were overweight or obese in 2022-2023, with 26.2% classified as obese. These figures were similar to those of the previous year, indicating a continued rise in obesity rates. This growing prevalence is expected to further drive demand for Saxenda.
The rising incidence of diabetes is also expected to boost the growth of the Saxenda market. Diabetes is a chronic condition that impairs the body's ability to regulate blood sugar levels, and its prevalence is rising due to unhealthy diets, sedentary lifestyles, obesity, aging populations, and genetic factors. Saxenda helps manage diabetes by leveraging liraglutide to improve insulin sensitivity, regulate blood sugar levels, and slow gastric emptying. This dual action supports both glycemic control and weight management. A report by Diabetes Canada in February 2023 indicated that nearly 30% of Ontario’s population, or about 2.4 million people, had diabetes or prediabetes, with a projected 25% increase in prevalence over the next decade. This rise is expected to drive up treatment costs from $1.7 billion to $2.1 billion annually by 2033, further contributing to the growth of the Saxenda market.
The trend fueling the Saxenda market is the development of generic products for weight management, which provide affordable alternatives to brand-name drugs. Generic medications are chemically identical to their branded counterparts, offering the same therapeutic effects but typically at a lower price. In April 2024, Biocon Limited, an India-based biopharmaceutical company, received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for its generic version of Saxenda, called Liraglutide (gSaxenda). This generic formulation, available as a 6 mg/ml solution in a pre-filled pen, is designed to aid in weight management when used alongside a reduced-calorie diet and increased physical activity. The approval of gSaxenda underscores the growing importance of cost-effective alternatives in addressing obesity, expanding the availability of treatment options and strengthening Biocon’s position in the market.
The countries covered in the saxenda market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Saxenda is a prescription medication containing liraglutide, designed to support weight management in adults with obesity or overweight conditions. It works by mimicking a natural hormone that regulates appetite, helping individuals reduce their caloric intake and achieve long-term weight loss when used alongside a reduced-calorie diet and increased physical activity.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Saxenda include obesity management (for individuals with a body mass index (BMI) of ≥30 kg/m²) and overweight management (for individuals with a BMI of ≥27 kg/m² to < 30 kg/m² who also have weight-related comorbidities). Obesity, defined as a BMI of 30 kg/m² or higher, is associated with an excess accumulation of body fat, significantly increasing the risk of chronic health issues such as type 2 diabetes, hypertension, and cardiovascular diseases. Saxenda is available in various forms, including injections and pre-filled pens, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The end users include hospitals, clinics, and homecare settings.
The saxenda market consists of sales of products such as prefilled pens of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing personalized medicine, expanding healthcare infrastructure, rising demand for non-surgical weight loss solutions, and increasing use of digital health tools. Major trends in the forecast period include the emergence of combination therapies for weight loss, increasing availability of prescription weight loss medications, rising adoption of digital health and fitness apps, integration of weight management solutions into primary care, and greater focus on sustainable lifestyle changes.
The increasing prevalence of obesity is expected to drive the growth of the Saxenda market in the coming years. Obesity, which is characterized by excessive body fat, increases the risk of various health conditions such as diabetes, heart disease, and certain cancers. Factors contributing to the rising prevalence of obesity include poor diets, sedentary lifestyles, urbanization, genetic predispositions, and hormonal imbalances. Saxenda aids in combating obesity by regulating appetite through liraglutide, an active ingredient that mimics the natural hormone GLP-1, promoting feelings of fullness, reducing caloric intake, and supporting sustainable weight loss when combined with a healthy diet and regular exercise. For example, according to a May 2024 report by the Office for Health Improvement and Disparities (OHID), around 64% of adults in England were overweight or obese in 2022-2023, with 26.2% classified as obese. These figures were similar to those of the previous year, indicating a continued rise in obesity rates. This growing prevalence is expected to further drive demand for Saxenda.
The rising incidence of diabetes is also expected to boost the growth of the Saxenda market. Diabetes is a chronic condition that impairs the body's ability to regulate blood sugar levels, and its prevalence is rising due to unhealthy diets, sedentary lifestyles, obesity, aging populations, and genetic factors. Saxenda helps manage diabetes by leveraging liraglutide to improve insulin sensitivity, regulate blood sugar levels, and slow gastric emptying. This dual action supports both glycemic control and weight management. A report by Diabetes Canada in February 2023 indicated that nearly 30% of Ontario’s population, or about 2.4 million people, had diabetes or prediabetes, with a projected 25% increase in prevalence over the next decade. This rise is expected to drive up treatment costs from $1.7 billion to $2.1 billion annually by 2033, further contributing to the growth of the Saxenda market.
The trend fueling the Saxenda market is the development of generic products for weight management, which provide affordable alternatives to brand-name drugs. Generic medications are chemically identical to their branded counterparts, offering the same therapeutic effects but typically at a lower price. In April 2024, Biocon Limited, an India-based biopharmaceutical company, received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for its generic version of Saxenda, called Liraglutide (gSaxenda). This generic formulation, available as a 6 mg/ml solution in a pre-filled pen, is designed to aid in weight management when used alongside a reduced-calorie diet and increased physical activity. The approval of gSaxenda underscores the growing importance of cost-effective alternatives in addressing obesity, expanding the availability of treatment options and strengthening Biocon’s position in the market.
The key company operating in the saxenda market is Novo Nordisk
North America was the largest region in the saxenda market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in saxenda report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the saxenda market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Saxenda is a prescription medication containing liraglutide, designed to support weight management in adults with obesity or overweight conditions. It works by mimicking a natural hormone that regulates appetite, helping individuals reduce their caloric intake and achieve long-term weight loss when used alongside a reduced-calorie diet and increased physical activity.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Saxenda include obesity management (for individuals with a body mass index (BMI) of ≥30 kg/m²) and overweight management (for individuals with a BMI of ≥27 kg/m² to < 30 kg/m² who also have weight-related comorbidities). Obesity, defined as a BMI of 30 kg/m² or higher, is associated with an excess accumulation of body fat, significantly increasing the risk of chronic health issues such as type 2 diabetes, hypertension, and cardiovascular diseases. Saxenda is available in various forms, including injections and pre-filled pens, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The end users include hospitals, clinics, and homecare settings.
The saxenda market consists of sales of products such as prefilled pens of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Saxenda Market Characteristics4. Saxenda Market Trends And Strategies5. Saxenda Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Saxenda Pricing Analysis & Forecasts30. Global Saxenda Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Saxenda Market32. Recent Developments In The Saxenda Market
3. Saxenda Market Biologic Drug Characteristics
6. Global Saxenda Growth Analysis And Strategic Analysis Framework
8. Saxenda Market Segmentation
9. Global Saxenda Epidemiology Of Clinical Indications
10. Saxenda Market Regional And Country Analysis
11. Asia-Pacific Saxenda Market
12. China Saxenda Market
13. India Saxenda Market
14. Japan Saxenda Market
15. Australia Saxenda Market
16. South Korea Saxenda Market
17. Western Europe Saxenda Market
18. UK Saxenda Market
19. Germany Saxenda Market
20. France Saxenda Market
21. Eastern Europe Saxenda Market
22. North America Saxenda Market
23. USA Saxenda Market
24. Canada Saxenda Market
25. South America Saxenda Market
26. Middle East Saxenda Market
27. Africa Saxenda Market
28. Saxenda Market Competitive Landscape And Company Profiles
29. Global Saxenda Market Pipeline Analysis
33. Saxenda Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Saxenda Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on saxenda market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for saxenda ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The saxenda market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Obesity Management (Body Mass Index (BMI) of ≥30 kg/m²); Overweight Management (BMI of ≥27 kg/m² to < 30 kg/m² with weight-related comorbidities)2) By Dosage Form: Injection; Pre-filled pens
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Hospitals And Clinics; Homecare Settings
Key Companies Profiled: Novo Nordisk
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novo Nordisk